Summary

Join us for an engaging webinar featuring presentations by renowned U.S. oncologists Dr. Hope Rugo and Dr. Komal Jhaveri. Together with respected Canadian moderator Dr. Jean-Pierre Ayoub, they will draw on both international and Canadian perspectives to deliver key clinical insights and practical strategies. Dr. Ayoub will bring a particular focus on the Canadian context throughout the discussion. The session will explore the management of adverse events associated with approved therapies in HR+/HER2- metastatic breast cancer and highlight practical approaches to optimizing patient care.


This activity has been funded by an educational grant from AstraZeneca and is intended for healthcare practitioners only.

Highlights

  • 1

    Understand the spectrum of AEs associated with current HR+/HER2- MBC therapies approved in Canada.

  • 2

    Explore strategies to monitor, mitigate, and personalize AE management in clinical practice.

  • 3

    Discuss the implications of emerging research on AE management for Canadian oncologists.

User

Hope S. Rugo, MD

Division Chief, Breast Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

User

Komal Jhaveri, MD, FACP

Section Head, Endocrine Therapy Research Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

User

Jean-Pierre Ayoub, MD, FRCPC

Medical Oncologist, Hematology-Oncology, CHUM, Montreal, Canada

Comments (0)